UPRET 30mg Retatrutide | Vial

UPRET 30mg is a vial labelled as containing 30mg of retatrutide. Retatrutide is an investigational triple hormone receptor agonist that activates GIP, GLP-1 and glucagon receptors involved in appetite, glucose regulation and energy metabolism.

What UPRET 30mg Is Used For

Retatrutide is currently being researched for:

Supporting body-weight reduction

Helping to reduce appetite and food intake

Supporting blood-glucose control

Improving certain metabolic health markers

Supporting the management of obesity and related metabolic conditions

How UPRET 30mg Works

Retatrutide simultaneously activates three metabolic hormone receptors:

GLP-1 receptors – involved in appetite, satiety and glucose regulation

GIP receptors – involved in insulin response and metabolic regulation

Glucagon receptors – involved in energy metabolism

This triple-receptor activity distinguishes retatrutide from single- and dual-receptor incretin therapies.

How to Use UPRET 30mg

The vial requires appropriate preparation before administration.

Retatrutide remains investigational and is not currently approved for public use, so there is no regulator-approved dosing schedule for commercially sold retatrutide products.

Administration Route: In clinical trials, retatrutide is administered by subcutaneous injection once weekly.

Dosage Information

Total labelled content per vial: 30mg Retatrutide

Clinical studies have evaluated different doses with gradual dose escalation. Because retatrutide remains investigational, dosing should be determined with appropriate professional medical guidance rather than assumed from non-approved product instructions.

Possible Side Effects

Clinical trials have most commonly reported gastrointestinal side effects, particularly during dose escalation.

Common

Nausea

Diarrhoea

Vomiting

Constipation

Decreased appetite